In cancer cachexia trials, measures of physical function are commonly used as endpoints.
For drug trials to obtain regulatory approval, efficacy in physical function endpoints may be …

Background: The utilization of herbal medicine has been noteworthy for treating cancer;
however, there is not enough information regarding the characteristics of clinical trials of …

There is no consensus on the optimal endpoint (s) in cancer cachexia trials. Endpoint
variation is an obstacle when comparing interventions and their clinical value. The aim of …

The use of patient‐reported outcomes (PROMs) of quality of life (QOL) is common in
cachexia trials. Patients' self‐report on health, functioning, wellbeing, and perceptions of …

As a worldwide public health issue, cancer‐induced cachexia can result in decreasing
physical function and survival rate. However, the therapeutic effects of conventional …

Simple Summary Symptom management in the cancer setting focuses on the improvement
of the overall quality of life and physical function, particularly for patients with muscle and …

Purpose Many therapeutic approaches have been studied for the treatment of cancer-
induced cachexia; however, except megestrol acetate, there is still no documented modality …

INTRODUCTION: Unintentional weight loss (UWL) is the main symptom of cachexia, a
multifactorial syndrome associated with advanced disease. Other symptoms include loss of …